Agios Pharmaceuticals Inc (AGIO)
31.48
-0.19
(-0.60%)
USD |
NASDAQ |
Apr 26, 16:00
31.48
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Enterprise Value: 1.003B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | 1.003B |
April 24, 2024 | 1.003B |
April 23, 2024 | 1.011B |
April 22, 2024 | 920.72M |
April 19, 2024 | 882.50M |
April 18, 2024 | 876.88M |
April 17, 2024 | 854.41M |
April 16, 2024 | 841.48M |
April 15, 2024 | 867.33M |
April 12, 2024 | 881.38M |
April 11, 2024 | 944.32M |
April 10, 2024 | 905.54M |
April 09, 2024 | 892.62M |
April 08, 2024 | 779.67M |
April 05, 2024 | 771.24M |
April 04, 2024 | 792.03M |
April 03, 2024 | 822.94M |
April 02, 2024 | 834.18M |
April 01, 2024 | 844.85M |
March 28, 2024 | 866.21M |
March 27, 2024 | 859.46M |
March 26, 2024 | 856.09M |
March 25, 2024 | 890.93M |
March 22, 2024 | 902.17M |
March 21, 2024 | 922.40M |
Date | Value |
---|---|
March 20, 2024 | 921.84M |
March 19, 2024 | 913.97M |
March 18, 2024 | 869.02M |
March 15, 2024 | 905.54M |
March 14, 2024 | 878.57M |
March 13, 2024 | 908.92M |
March 12, 2024 | 925.21M |
March 11, 2024 | 953.87M |
March 08, 2024 | 981.41M |
March 07, 2024 | 985.90M |
March 06, 2024 | 1.010B |
March 05, 2024 | 985.90M |
March 04, 2024 | 1.031B |
March 01, 2024 | 1.036B |
February 29, 2024 | 1.039B |
February 28, 2024 | 1.115B |
February 27, 2024 | 1.179B |
February 26, 2024 | 1.070B |
February 23, 2024 | 1.077B |
February 22, 2024 | 896.55M |
February 21, 2024 | 729.09M |
February 20, 2024 | 745.95M |
February 16, 2024 | 712.80M |
February 15, 2024 | 729.09M |
February 14, 2024 | 678.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.17M
Minimum
Jun 14 2022
3.415B
Maximum
Feb 11 2021
1.377B
Average
1.015B
Median
Enterprise Value Benchmarks
Alnylam Pharmaceuticals Inc | 16.68B |
Blueprint Medicines Corp | 5.084B |
Corcept Therapeutics Inc | 1.931B |
Ionis Pharmaceuticals Inc | 5.050B |
Madrigal Pharmaceuticals Inc | 3.349B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -95.94M |
Revenue (Quarterly) | 7.103M |
Total Expenses (Quarterly) | 113.38M |
EPS Diluted (Quarterly) | -1.72 |
Gross Profit Margin (Quarterly) | 91.75% |
Profit Margin (Quarterly) | -1.35K% |
Earnings Yield | -20.14% |
Normalized Earnings Yield | -20.14 |